$QLGN News
Last published 12mo ago
- 12mo agoQLGNAIXCQualigen Therapeutics Stockholders Approve All Proposals with Majority Vote; Company to Rebrand as AIxCrypto Holdings, Inc. (Nasdaq: AIXC) Following November 20 Nasdaq Ceremony and Announces Transition into AI × Web3 StrategyGlobeNewswireShareholders approved all proposals, confirming Faraday Future Intelligent Electric Inc. ("Faraday Future") as the Company's new majority and controlling shareholder.Faraday Future will nominate a majority of board seats
- 1y agoFFAIQLGNQualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025GlobeNewswireDubai, UAE / Beijing, China, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics Inc. (NASDAQ:QLGN) ("Qualigen", "QLGN" or the "Company"), a publicly-traded technology company majority owned by Faraday Future
- 1y agoQLGNQualigen Therapeutics Partners with BitGo to Execute First Multi-Asset C10 Treasury AllocationGlobeNewswireNew York, NY, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics Inc. (NASDAQ:QLGN) ("Qualigen", "QLGN" or "Company"), a publicly-trading technology company majority owned by Faraday Future, today announced a
- 1y agoQLGNQualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment CXC10 Has Been Waiting For?GlobeNewswireCarlsbad, CA, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") today announced the official launch of C10 Cryptocurrency Asset Treasury (DAT) purchases: Why is this pullback
- 1y agoQLGNQualigen Therapeutics (NASDAQ: QLGN) Announces Executives, Board of Directors Appointments and Auditor TransitionGlobeNewswireCarlsbad, CA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") today announced a series of key leadership and governance changes aimed at strengthening its executive team,
- 1y agoFFAIQLGNUnivest Securities, LLC Announces Closing of $41 Million Strategic Investment in Client Qualigen Therapeutics (NASDAQ: QLGN) from Client Faraday Future (NASDAQ: FFAI)GlobeNewswireNew York, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the
- 1y agoFFAIQLGNQualigen Therapeutics Announces Successful Closing of $41 Million PIPE Financing Led by Faraday Future, Accelerating New Business Transformation into CryptoGlobeNewswireCarlsbad, CA, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or "the Company") today announced the successful closing of a $41 million private investment in public equity
- 1y agoFFAIQLGNFaraday Future Announces Closing of Strategic $41 Million Investment in Qualigen Therapeutics (NASDAQ: QLGN) to Accelerate its Dual-Flywheel & Dual-Bridge Eco StrategyGlobeNewswireQLGN is expected to rebrand as CXC10 soon, reflecting its new strategic direction around crypto and web3 business. LOS ANGELES, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ:FFAI)
- 1y agoFFAIQLGNFaraday Future Announced a Total Strategic Investment of $41 million in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) During its Annual 919 Event, for its Crypto Business Focusing on Three Growth EnginesGlobeNewswireFaraday Future is making an investment of approximately $30 million in Qualigen Therapeutics ("QLGN"); FF Founder and Co-CEO YT Jia will invest approximately $4 million (via an FFGP loan) in QLGN with a two-year
- 1y agoFFAIQLGNFaraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) for Crypto Business Through PIPE TransactionGlobeNewswireLOS ANGELES and CARLSBAD, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ:FFAI) ("Faraday Future", "FF" or "Company"), a California-based global shared intelligent electric
- 1y agoFFAIQLGNFaraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) f for Crypto Business Through PIPE TransactionGlobeNewswireLOS ANGELES and CARLSBAD, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ:FFAI) ("Faraday Future", "FF" or "Company"), a California-based global shared intelligent electric mobility
- 1y agoQLGNQualigen Therapeutics Provides Update on Nasdaq Communications and Continued Listing StatusGlobeNewswireCARLSBAD, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") received two different communications from the staff of the Nasdaq Listing Qualifications office of the
- 1y agoQLGNQualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred StockGlobeNewswireCarlsbad, CA, July 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or the "Company"), a life sciences company focused on developing platform treatments for adult and
- 1y agoQLGNQualigen Granted New Patents Covering 25 CountriesGlobeNewswireCARLSBAD, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company" or "Qualigen") is announcing an update on patents granted in the first six months of 2025. The patent is
- 1y agoQLGNQualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-QGlobeNewswireCARLSBAD, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") announced today that it received an expected deficiency notification letter from the Listing Qualifications
- 1y agoQLGNQualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-KGlobeNewswireCARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") announced today that it received an expected deficiency notification letter from the Listing Qualifications
- 1y agoQLGNQualigen to participate in next funding round for NanoSynexGlobeNewswireMarket size expected to reach $4.7 billion in 2027 CARLSBAD, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company")announced today they will be the first investors
- 1y agoQLGNQualigen Therapeutics Announces Regained Compliance with Nasdaq's Minimum Bid Price Requirement and the Equity RequirementGlobeNewswireCarlsbad, CA, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics (NASDAQ:QLGN) (the "Company" or "Qualigen") today announced that the Company received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") that
- 1y agoQLGNUnivest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN)GlobeNewswireNew York, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the
- 1y agoQLGNQualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred SharesGlobeNewswireCarlsbad, CA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or the "Company"), Qualigen Therapeutics, Inc., is a life science company focused on developing
- 2y agoQLGNShares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024GlobeNewswireCARLSBAD, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") announced today that it will implement a 1-for-50 reverse stock split of the issued shares of its common
- 2y agoQLGNQualigen Therapeutics, Inc. Announces management changes.GlobeNewswireCARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") announced on September 23, 2024, Mr. Michael Poirier, notified the board of directors of the Company (the
- 2y agoQLGNQualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings PanelGlobeNewswireCARLSBAD, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") today announced that on September 11, 2024, the Company received a notice from Nasdaq indicating that the
- 2y agoQLGNUnivest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN)GlobeNewswireNew York, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the
- 2y agoQLGNQualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public OfferingGlobeNewswireCARLSBAD, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") today announced the closing of its previously announced public offering of 14,724,058 shares of common
- 2y agoQLGNQualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public OfferingGlobeNewswireCARLSBAD, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") today announced the pricing of a public offering of 14,724,058 shares of common stock, par value $0.001 per
- 2y agoANEBLFCRLGNDQLGNLifecore Biomedical Announces Cooperation Agreement with 22NWGlobeNewswireCHASKA, Minn., July 01, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced
- 2y agoQLGNQualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting DeterminationGlobeNewswireCARLSBAD, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (("Qualigen" or "the Company, NASDAQ:QLGN), announced today that on May 23, 2024, it received written notice (the "Delist Notice") from The
- 2y agoQLGNQualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual MeetingGlobeNewswirePoster Includes Preclinical Data on Novel Direct Pan-RAS Inhibitors CARLSBAD, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (("Qualigen" or "the Company, NASDAQ:QLGN) today announces a
- 2y agoQLGNQualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual MeetingGlobeNewswireCARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (("Qualigen" or the "Company, NASDAQ:QLGN) today announces that a poster featuring its early clinical experience with a novel
- 2y agoQLGNQualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023GlobeNewswireInitiated dosing of three patients in first cohort of Phase 1 clinical trial of QN-302 for treatment of advanced or metastatic solid tumorsPhase 1a patient recruitment ongoing; company anticipates sharing update on
- 3y agoQLGNQualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid TumorsGlobeNewswireCARLSBAD, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for
- 3y agoQLGNPoster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast CancerGlobeNewswirePoster Includes Preclinical Data on Pan-RAS Compounds Demonstrating Inhibition in Breast Cancer Models CARLSBAD, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a
- 3y agoQLGNQualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023GlobeNewswireTwo posters include data on potential clinical biomarkers and transcriptomic data associated with QN-302's mechanism of action CARLSBAD, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc.
- 3y agoQLGNQualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid TumorsGlobeNewswireCARLSBAD, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for
- 3y agoQLGNQualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023GlobeNewswireInvestigational New Drug (IND) clearance transitions Qualigen from preclinical to clinical-stage company Company divests FastPack® diagnostics business for approximately $5 million in all cash transaction to
- 3y agoQLGNQualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid TumorsGlobeNewswireInvestigational New Drug (IND) clearance transitions Qualigen Therapeutics from preclinical to clinical-stage company and demonstrates leadership in G4-targeting therapies for areas of high unmet need in oncology
- 3y agoQLGNQualigen Therapeutics Divests FastPack® Diagnostics BusinessGlobeNewswireAll cash deal with Chembio Diagnostics, a US Subsidiary of the French Diagnostics Company BIOSYNEX, SA, solidifies Qualigen's strategic priority on therapeutics CARLSBAD, Calif., July 24, 2023 (GLOBE NEWSWIRE) --
- 3y agoQLGNPoster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual MeetingGlobeNewswirePreclinical Data Show Potential to Overcome Resistance to Key KRAS-G12C Therapeutic Compounds CARLSBAD, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a diversified life
- 3y agoQLGNQualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023GlobeNewswireCompany Reports 123% Increase in Year-Over-Year Revenue CARLSBAD, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a diversified life sciences company focused on developing
- 3y agoQLGNQualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate UpdateGlobeNewswireCARLSBAD, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN, Inc.)), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential
- 3y agoQLGNQualigen Therapeutics' Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual MeetingGlobeNewswireAbstracts Feature Preclinical Data in (1) Pancreatic Cancer and (2) Luminal B Breast Cancer CARLSBAD, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a diversified life sciences
- 3y agoQLGNQualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K FilingGlobeNewswireCARLSBAD, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (("Qualigen" or "the Company, NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric
- 3y agoQLGNQualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FLGlobeNewswireCARLSBAD, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (("Qualigen" or "the Company, NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric
- 3y agoQLGNQualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FLGlobeNewswireIn Vivo Efficacy Study Demonstrates QN-247 as Potential Therapeutic Approach in Rare Breast Cancer Type CARLSBAD, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (("Qualigen" or "the Company,
- 3y agoQLGNComposition of Matter Patent for QN-302 Granted by United States Patent and Trademark OfficeGlobeNewswireCARLSBAD, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (("Qualigen" or "the Company, NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric
- 3y agoQLGNQualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023GlobeNewswireCARLSBAD, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (("Qualigen" or "the Company, NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric
- 3y agoQLGNQualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS ConferenceGlobeNewswireData demonstrates potential anti-RAS activity with Qualigen's novel RAS small molecule in both pancreatic and breast cancer in vivo models CARLSBAD, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Qualigen
- 3y agoQLGNData on Potential Biomarker for Qualigen Therapeutics' Lead Program QN-302 Published in Peer-Reviewed Journal MoleculesGlobeNewswireS100P Gene Expression May Be Marker of Anti-Tumor Activity in Pancreatic Cancer In Vivo Models CARLSBAD, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (("Qualigen" or "the Company,
- 3y agoQLGNQualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to StockholdersGlobeNewswireCARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (("Qualigen" or "the Company, NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric